Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.74 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.74 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.74 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3541919 | 0.85 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3551340 | 0.85 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5245139 | 0.80 | MAPK14 (0.67) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3543311 | 0.80 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3174216 | 0.78 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL27621816 | 0.77 | MAPK14 (0.80) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL13234492 | 0.77 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL27621817 | 0.76 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL27621814 | 0.75 | MAPK14 (0.75) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL13297062 | 0.75 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167247-A1 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | claimed |
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20060167247-A1 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167247-A1 | Urea inhibitors of MAP kinases | MAPK1, MAP3K1, MAP3K20 | MAPK14 47/4885MAPK13 52/4885MAPK12 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.